Varenicline Ameliorates Nicotine Withdrawal-Induced Learning Deficits in C57BL/6 Mice

Behavioral Neuroscience

Volumn 122, Issue 5, 2008, Pages 1166-1171

  Raybuck, Jonathan D ^a   Portugal, George S ^a   Lerman, Caryn ^b   Gould, Thomas J ^a  

^a TEMPLE UNIVERSITY   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

acetylcholine; addiction; cognition; hippocampus; withdrawal

Indexed keywords

NICOTINE; VARENICLINE;

ANIMAL EXPERIMENT; ARTICLE; C57BL 6 MOUSE; CONDITIONING; DRUG EFFECT; FEAR; LEARNING; MALE; MEMORY; MOUSE; NONHUMAN;

ANIMALS; BEHAVIOR, ANIMAL; BENZAZEPINES; CONDITIONING (PSYCHOLOGY); DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEAR; FREEZING REACTION, CATALEPTIC; LEARNING DISORDERS; MALE; MICE; MICE, INBRED C57BL; NICOTINIC AGONISTS; QUINOXALINES; TOBACCO USE DISORDER;

EID: 54049096015     PISSN: 07357044     EISSN: None     Source Type: Journal    
DOI: 10.1037/a0012601     Document Type: Article

References (47)

1. André J.M., Gulick D., Portugal G.S., and Gould T.J. Nicotine withdrawal disrupts both foreground and background contextual fear conditioning but not pre-pulse inhibition of the acoustic startle response in C57BL/6 mice. Behavioral Brain Research 190 (2008) 174-181
2. Bell S.L., Taylor R.C., Singleton E.G., Henningfield J.E., and Heishman S.J. Smoking after nicotine deprivation enhances cognitive performance and decreases tobacco craving in drug abusers. Nicotine Tobacco Research 1 (1999) 45-52
3. Benowitz N.L. Pharmacologic aspects of cigarette smoking and nicotine addiction. The New England Journal of Medicine 391 (1988) 1319
4. Benowitz N.L., Kuyt F., and Jacob III P. Circadian blood nicotine concentrations during cigarette smoking. Clinical Pharmacology and Therapeutics 32 (1982) 758-764
5. Benowitz N.L., Porchet H., and Jacob III P. Nicotine dependence and tolerance in man: Pharmacokinetic and pharmacodynamic investigations. Progress in Brain Research 79 (1989) 279-287
6. Benowitz N.L., Porchet H., Sheiner L., and Jacob III P. Nicotine absorption and cardiovascular effects with smokeless tobacco use: Comparison with cigarettes and nicotine gum. Clinical Pharmacology and Therapeutics 44 (1988) 23-28
7. Blake J., and Smith A. Effects of smoking deprivation on the articulatory loop of working memory. Human Psychopharmacology 12 (1997) 259-264
8. Blanchard R.J., and Blanchard D.C. Crouching as an index of fear. Journal of Comparative Physiology. A, Sensory, Neural, and Behavioral Physiology Psychology 67 (1969) 370-375
9. CDC. Annual smoking-attributable mortality, years of potential life lost, and productivity losses-United States, 1997-2001. Morbidity and Mortality Weekly Report 54 (2005) 625-628
10. Coe J.W., Brooks P.R., Vetelino M.G., Wirtz M.C., Arnold E.P., Huang J., et al. Varenicline: An alpha4beta2 nicotinic receptor partial agonist for smoking cessation. Journal of Medicinal Chemistry 48 (2005) 3474-3477
11. Cohen B.H. Explaining psychological statistics. 2nd ed. (2001), Wiley, New York
12. Davis J.A., and Gould T.J. Atomoxetine reverses nicotine withdrawal-associated deficits in contextual fear conditioning. Neuropsychopharmacology 32 (2007) 2011-2019
13. Davis J.A., James J.R., Siegel S.J., and Gould T.J. Withdrawal from chronic nicotine administration impairs contextual fear conditioning in C57BL/6 mice. Journal of Neuroscience 25 (2005) 8708-8713
14. Davis J.A., Kenney J.W., and Gould T.J. Hippocampal alpha4beta2 nicotinic acetylcholine receptor involvement in the enhancing effect of acute nicotine on contextual fear conditioning. Journal of Neuroscience 27 (2007) 10870-10877
15. Davis J.A., Porter J., and Gould T.J. Nicotine enhances both foreground and background contextual fear conditioning. Neuroscience Letters 394 (2006) 202-205
16. Department of Health and Human Services, Public Health Service. The health consequences of smoking: Nicotine addiction: A report of the surgeon general (DHHS Publication No. CDC 88-8406) (1988), U.S. Government Printing Office, Washington, DC
17. Fanselow M.S. Contextual fear, gestalt memories, and the hippocampus. Behavioural Brain Research 110 1-2 (2000) 73-81
18. Frishman W.H., Mitta W., Kupersmith A., and Ky T. Nicotine and non-nicotine smoking cessation pharmacotherapies. Cardiology Review 14 (2006) 57-73
19. Gonzales D., Rennard S.I., Nides M., Oncken C., Azoulay S., Billing C.B., et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: A randomized controlled trial. Journal of the American Medical Association 296 (2006) 47-55
20. Gould T.J., and Wehner J.M. Nicotine enhancement of contextual fear conditioning. Behavioural Brain Research 102 (1999) 31-39
21. Grady S.R., Salminen O., Laverty D.C., Whiteaker P., McIntosh J.M., Collins A.C., et al. The subtypes of nicotinic acetylcholine receptors on dopaminergic terminals of mouse striatum. Biochemical Pharmacology 74 (2007) 1235-1246
22. Henningfield J.E., and Keenan R.M. Nicotine delivery kinetics and abuse liability. Journal of Consulting and Clinical Psychology 61 (1993) 743-750
23. Hughes J.R. Effects of abstinence from tobacco: Valid symptoms and time course. Nicotine and Tobacco Research 9 (2007) 315-327
24. Hughes J.R., Gust S.W., Skoog K., Keenan R.M., and Fenwick J.W. Symptoms of tobacco withdrawal. A replication and extension. Archives of General Psychiatry 48 (1991) 52-59
25. Hughes J.R., Higgins S.T., and Bickel W.K. Nicotine withdrawal versus other drug withdrawal syndromes: Similarities and dissimilarities. Addiction 89 (1994) 1461-1470
26. Hughes J.R., Keenan R.M., and Yellin A. Effect of tobacco withdrawal on sustained attention. Addictive Behaviors 14 (1989) 577-580
27. Jacobsen L.K., Krystal J.H., Mencl W.E., Westerveld M., Frost S.J., and Pugh K.R. Effects of smoking and smoking abstinence on cognition in adolescent tobacco smokers. Biological Psychiatry 57 (2005) 56-66
28. Jacobsen L.K., Mencl W.E., Constable R.T., Westerveld M., and Pugh K.R. Impact of smoking abstinence on working memory neurocircuitry in adolescent daily tobacco smokers. Psychopharmacology (Berlin) 193 (2007) 557-566
29. Jarvis M.J. Why people smoke. British Medical Journal 328 (2004) 277-279
30. Jorenby D.E., Hays J.T., Rigotti N.A., Azoulay S., Watsky E.J., Williams K.E., et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: A randomized controlled trial. Journal of the American Medical Association 296 (2006) 56-63
31. Lerman C., LeSage M.G., Perkins K.A., O'Malley S.S., Siegel S.J., Benowitz N.L., et al. Translational research in medication development for nicotine dependence. Nature Reviews. Drug Discovery 6 (2007) 746-762
32. Mao D., Perry D.C., Yasuda R.P., Wolfe B.B., and Kellar K.J. The alpha4beta2alpha5 nicotinic cholinergic receptor in rat brain is resistant to up-regulation by nicotine in vivo. Journal of Neurochemistry 104 (2008) 446-456
33. Maxwell S.E., and Delaney H.D. Designing experiments and analyzing data: A model comparison perspective. 2nd ed. (2003), Erlbaum, Mahwah, NJ
34. Mendrek A., Monterosso J., Simon S.L., Jarvik M., Brody A., Olmstead R., et al. Working memory in cigarette smokers: Comparison to non-smokers and effects of abstinence. Addictive Behaviors 31 (2006) 833-844
35. Mihalak K.B., Carroll F.I., and Luetje C.W. Varenicline is a partial agonist atalpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors. Molecular Pharmacology 70 (2006) 801-805
36. Mokdad A.H., Marks J.S., Stroup D.F., and Gerberding J.L. Actual causes of death in the United States, 2000. Journal of the American Medical Association 291 (2004) 1238-1245
37. Nakamura M., Oshima A., Fujimoto Y., Maruyama N., Ishibashi T., and Reeves K.R. Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers. Clinical Therapeutics 29 (2007) 1040-1056
38. Nides M., Oncken C., Gonzales D., Rennard S., Watsky E.J., Anziano R., et al. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: Results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Archives of Internal Medicine 166 (2006) 1561-1568
39. Portugal G.S., and Gould T.J. Bupropion dose-dependently reverses nicotine withdrawal deficits in contextual fear conditioning. Pharmacology, Biochemistry and Behavior 88 (2007) 179-187
40. Portugal G.S., Kenney J.W., and Gould T.J. beta2 subunit containing acetylcholine receptors mediate nicotine withdrawal deficits in the acquisition of contextual fear conditioning. Neurobiology of Learning and Memory 89 (2008) 106-113
41. Rice D.P. Economic costs of substance abuse, 1995. Proceedings of the Association of American Physicians 111 (1999) 119-125
42. Rollema H., Chambers L.K., Coe J.W., Glowa J., Hurst R.S., Lebel L.A., et al. Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology 52 (2007) 985-994
43. Rukstalis M., Jepson C., Patterson F., and Lerman C. Increases in hyperactive-impulsive symptoms predict relapse among smokers in nicotine replacement therapy. Journal of Substance Abuse Treatment 28 (2005) 297-304
44. Schnoll R.A., and Lerman C. Current and emerging pharmacotherapies for treating tobacco dependence. Expert Opinion on Emerging Drugs 11 (2006) 429-444
45. Tonstad S., Tonnesen P., Hajek P., Williams K.E., Billing C.B., and Reeves K.R. Effect of maintenance therapy with varenicline on smoking cessation: A randomized controlled trial. Journal of the American Medical Association 296 (2006) 64-71
46. Wehner J.M., Keller J.J., Keller A.B., Picciotto M.R., Paylor R., Booker T.K., et al. Role of neuronal nicotinic receptors in the effects of nicotine and ethanol on contextual fear conditioning. Neuroscience 129 (2004) 11-24
47. Wu P., Wilson K., Dimoulas P., and Mills E.J. Effectiveness of smoking cessation therapies: A systematic review and meta-analysis. BMC Public Health 6 (2006) 300